A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer
Status:
Recruiting
Trial end date:
2026-07-25
Target enrollment:
Participant gender:
Summary
This study is open to adults with small cell lung cancer and other neuroendocrine cancers.
The study is in people with advanced cancer for whom previous treatment was not successful or
no standard treatment exists. The purpose of this study is to find out how a medicine called
BI 764532 gets distributed in the body and in tumours.
Participants get BI 764532 when starting treatment. In the first weeks, doctors check how BI
764532 is taken up in tumours by means of an imaging method. If there is benefit for the
participants and if they can tolerate it, the treatment is given up to the maximum duration
of the study. During this time, participants visit the study site regularly. The total number
of visits depends on how they respond to and tolerate the treatment. Doctors record any
unwanted effects and regularly check the general health of the participants.